Investigating a new target to improve chemotherapy effectiveness in bladder cancer
NPEPPS is a novel and druggable determinant of chemotherapy resistance in bladder cancer
This study is looking at ways to make chemotherapy work better for people with muscle-invasive bladder cancer by targeting a specific protein that affects how cancer cells react to treatment, which could help improve results and shrink tumors.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cedars-Sinai Medical Center NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-11114489 on NIH RePORTER |
What this research studies
This research focuses on enhancing the effectiveness of cisplatin-based chemotherapy for patients with muscle-invasive bladder cancer (MIBC). By utilizing advanced CRISPR-Cas9 technology, the study aims to identify and target a specific protein, NPEPPS, which influences how cancer cells respond to treatment. The researchers will explore how manipulating NPEPPS can improve treatment outcomes and reduce tumor growth in laboratory models. This approach could lead to new strategies for overcoming chemotherapy resistance in bladder cancer patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with muscle-invasive bladder cancer who are scheduled to receive cisplatin-based neoadjuvant chemotherapy.
Not a fit: Patients with non-muscle-invasive bladder cancer or those who are not receiving cisplatin-based chemotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve survival rates for bladder cancer patients who currently do not respond well to chemotherapy.
How similar studies have performed: Previous research has shown promising results using CRISPR technology to identify and target cancer resistance mechanisms, indicating potential for success in this novel approach.
Where this research is happening
Los Angeles, United States
- Cedars-Sinai Medical Center — Los Angeles, United States (Active)
Researchers
- Principal investigator: Theodorescu, Dan — Cedars-Sinai Medical Center
- Study coordinator: Theodorescu, Dan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.